(19)
(11) EP 4 583 873 A2

(12)

(88) Date of publication A3:
25.04.2024

(43) Date of publication:
16.07.2025 Bulletin 2025/29

(21) Application number: 23863922.3

(22) Date of filing: 01.09.2023
(51) International Patent Classification (IPC): 
A61K 31/444(2006.01)
C07D 471/04(2006.01)
 A61K 31/4745(2006.01)
A61K 38/31(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/4745; A61P 35/00; G01N 33/57407
(86) International application number:
PCT/US2023/073348
(87) International publication number:
WO 2024/054785 (14.03.2024 Gazette 2024/11)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 06.09.2022 US 202263404130 P

(71) Applicant: Corcept Therapeutics Incorporated
Redwood City, CA 94065 (US)

(72) Inventors:
  • GREENSTEIN, Andrew
    Menlo Park, California 94025 (US)
  • MORAITIS, Andreas
    Menlo Park, California 94025 (US)
  • ZAVROS, Yana
    Tucson, Arizona 85719 (US)

(74) Representative: Geling, Andrea 
ZSP Patentanwälte PartG mbB Hansastraße 32
80686 München
80686 München (DE)

   


(54) GENETICALLY ENGINEERED HUMAN PITUITARY CORTICOTROPH TUMOR ORGANOIDS EXHIBIT DIVERGENT RESPONSES TO SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS